umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis: Results from the TYNERGY Trial: A Study in the Real Life Setting
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience, Clinical Neuroscience.
Show others and affiliations
2013 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 8, no 3, e58643- p.Article in journal (Refereed) Published
Abstract [en]

Fatigue is a significant symptom in multiple sclerosis (MS) patients. First-generation disease modifying therapies (DMTs) are at best moderately effective to improve fatigue. Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related fatigue. The TYNERGY study aimed to further evaluate the effects of natalizumab treatment on MS-related fatigue. In this one-armed clinical trial including 195 MS patients, natalizumab was prescribed in a real-life setting, and a validated questionnaire, the Fatigue Scale for Motor and Cognitive functions (FSMC), was used both before and after 12 months of treatment to evaluate a possible change in the fatigue experienced by the patients. In the treated cohort all measured variables, that is, fatigue score, quality of life, sleepiness, depression, cognition, and disability progression were improved from baseline (all p values<0.0001). Walking speed as measured by the six-minute walk-test also increased at month 12 (p = 0.0016). All patients were aware of the nature of the treatment agent, and of the study outcomes.

Conclusion: Natalizumab, as used in a real-life setting, might improve MS-related fatigue based on the results from this one-armed un-controlled stud. Also other parameters related to patients' quality of life seemed to improve with natalizumab treatment.

Place, publisher, year, edition, pages
Public Library Science , 2013. Vol. 8, no 3, e58643- p.
National Category
Neurology
Identifiers
URN: urn:nbn:se:umu:diva-68478DOI: 10.1371/journal.pone.0058643ISI: 000316546400008OAI: oai:DiVA.org:umu-68478DiVA: diva2:618156
Available from: 2013-04-26 Created: 2013-04-22 Last updated: 2017-12-06Bibliographically approved

Open Access in DiVA

Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis: Results from the TYNERGY Trial: A Study in the Real Life Setting(491 kB)345 downloads
File information
File name FULLTEXT02.pdfFile size 491 kBChecksum SHA-512
9c26666c2439ab0e587bc061b1193b238b26007762e18c5503ca8a285da3464faa5d48727a8fbe86f6103c6c3090d39ac1ece521ea9a09980efcfd39744bf360
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Svenningsson, Anders
By organisation
Clinical Neuroscience
In the same journal
PLoS ONE
Neurology

Search outside of DiVA

GoogleGoogle Scholar
Total: 345 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 107 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf